Javascript must be enabled to continue!
ARTEMIDE-HCC01: A phase 3, randomized, open-label, sponsor-blinded, multicentre, global study of rilvegostomig in combination with bevacizumab with or without tremelimumab as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC).
View through CrossRef
TPS612
Background:
HCC is the most common liver cancer, accounting for 80–90% globally and often diagnosed late. 1L treatment comprises immunotherapy combinations but outcomes remain poor due to diverse tumor immune-evasive mechanisms. New immunotherapy approaches are needed; combining checkpoint inhibitors (cytotoxic T lymphocyte associated protein 4, programmed cell death-1 [PD-1], and T cell immunoreceptor with Ig and ITIM domains [TIGIT]) with anti-vascular endothelial growth factor is one such approach. Rilvegostomig is a novel bispecific anti-PD-1/anti-TIGIT antibody designed to enhance antitumor activity by overcoming immune-inhibitory signaling. The phase 3 ARTEMIDE-HCC01 study (NCT06921785) will assess efficacy and safety of rilvegostomig plus bevacizumab with/without tremelimumab as 1L treatment for uHCC.
Methods:
Eligible patients will have confirmed uHCC, no prior systemic therapy, BCLC stage B (not eligible for locoregional therapy)/C, ECOG performance status 0/1, and Child-Pugh class A. This study comprises a safety lead-in and a randomization period. The single-arm safety lead-in period (N=20) will evaluate safety/tolerability of rilvegostomig plus bevacizumab and tremelimumab. In the randomization period, ~1200 patients will be randomized 1:1:1 to receive tremelimumab, rilvegostomig and bevacizumab (arm A), rilvegostomig and bevacizumab (arm B), or atezolizumab and bevacizumab (arm C) until progression/unacceptable toxicity. Randomization will be stratified by macrovascular invasion/extrahepatic spread, liver disease etiology, alpha-fetoprotein level, and programmed death-ligand 1 expression. Primary and secondary endpoints of the safety lead-in period are safety/tolerability and efficacy (objective response rate [ORR]), respectively. The primary endpoint of the randomized period will be overall survival (OS) (arm A vs arm C). Other endpoints include OS (arm B vs arm C), ORR, duration of response, progression-free survival, safety, and quality of life. Enrollment began in May 2025 and is ongoing.
Clinical trial information:
NCT06921785
.
American Society of Clinical Oncology (ASCO)
Title: ARTEMIDE-HCC01: A phase 3, randomized, open-label, sponsor-blinded, multicentre, global study of rilvegostomig in combination with bevacizumab with or without tremelimumab as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC).
Description:
TPS612
Background:
HCC is the most common liver cancer, accounting for 80–90% globally and often diagnosed late.
1L treatment comprises immunotherapy combinations but outcomes remain poor due to diverse tumor immune-evasive mechanisms.
New immunotherapy approaches are needed; combining checkpoint inhibitors (cytotoxic T lymphocyte associated protein 4, programmed cell death-1 [PD-1], and T cell immunoreceptor with Ig and ITIM domains [TIGIT]) with anti-vascular endothelial growth factor is one such approach.
Rilvegostomig is a novel bispecific anti-PD-1/anti-TIGIT antibody designed to enhance antitumor activity by overcoming immune-inhibitory signaling.
The phase 3 ARTEMIDE-HCC01 study (NCT06921785) will assess efficacy and safety of rilvegostomig plus bevacizumab with/without tremelimumab as 1L treatment for uHCC.
Methods:
Eligible patients will have confirmed uHCC, no prior systemic therapy, BCLC stage B (not eligible for locoregional therapy)/C, ECOG performance status 0/1, and Child-Pugh class A.
This study comprises a safety lead-in and a randomization period.
The single-arm safety lead-in period (N=20) will evaluate safety/tolerability of rilvegostomig plus bevacizumab and tremelimumab.
In the randomization period, ~1200 patients will be randomized 1:1:1 to receive tremelimumab, rilvegostomig and bevacizumab (arm A), rilvegostomig and bevacizumab (arm B), or atezolizumab and bevacizumab (arm C) until progression/unacceptable toxicity.
Randomization will be stratified by macrovascular invasion/extrahepatic spread, liver disease etiology, alpha-fetoprotein level, and programmed death-ligand 1 expression.
Primary and secondary endpoints of the safety lead-in period are safety/tolerability and efficacy (objective response rate [ORR]), respectively.
The primary endpoint of the randomized period will be overall survival (OS) (arm A vs arm C).
Other endpoints include OS (arm B vs arm C), ORR, duration of response, progression-free survival, safety, and quality of life.
Enrollment began in May 2025 and is ongoing.
Clinical trial information:
NCT06921785
.
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
ARTEMIDE-Lung03: A phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer
ARTEMIDE-Lung03: A phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer
TPS8653
Background:
In the United States, non-squamous histology accounts for approximately 70% of all non-small-cell lung cancers (NS...
T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma
T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma
Abstract
Purpose:
In the phase I/II Study 22 (NCT02519348) trial, objective response rates were 24.0% with STRIDE (single...
Data from T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma
Data from T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma
<div>AbstractPurpose:<p>In the phase I/II Study 22 (NCT02519348) trial, objective response rates were 24.0% with STRIDE (single tremelimumab regular-interval durvalumab...
A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.
A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.
TPS4199 Background: Biliary tract cancer (BTC) is a rare but aggressive heterogenous group of gastrointestinal cancers that arise from the intra- or extrahepatic bile ducts (chola...
Evaluating the GALAD Score in Diagnosing Hepatocellular Carcinoma
Evaluating the GALAD Score in Diagnosing Hepatocellular Carcinoma
This paper aims to evaluate the GALAD score in diagnosing hepatocellular carcinoma. The paper conducted a retrospective study of 86 Hepatocellular Carcinoma patients who underwent ...
Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice
Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice
Abstract
Bevacizumab-containing protocols are all based upon the concomitant administration of the drugs given in a row. Bevacizumab is expected to induce a transien...

